Aim: Familial apolipoprotein C-Ⅱ (apoC-Ⅱ) deficiency is a rare autosomal recessive disorder with marked hypertriglyceridemia resulting from impaired activation of lipoprotein lipase. In most cases of apoC-Ⅱ deficiency, causative mutations have been found in the protein-coding region of APOC2; however, several atypical cases of apoC-Ⅱ deficiency were reported to have markedly reduced, but detectable levels of plasma apoC-Ⅱ protein (hereafter referred to as hypoapoC-Ⅱ), which resulted from decreased promoter activity or improper splicing of apoC-Ⅱ mRNA due to homozygous mutations in APOC2. Here we aim to dissect the molecular bases of a new case of hypoapoC-Ⅱ. Methods: We performed detailed biochemical/genetic analyses of our new case of hypoapoC-Ⅱ, manifesting severe hypertriglyceridemia (plasma triglycerides, 3235 mg · dL −1 ) with markedly reduced levels of plasma apoC-Ⅱ (0.6 mg · dL −1 ). Results: We took advantage of a monocyte/macrophage culture system to prove that transcription of apoC-Ⅱ mRNA was decreased in the patient's cells, which is compatible with the reported features of hypoapoC-Ⅱ. Concomitantly, transcriptional activity of the minigene reporter construct of the patient's APOC2 gene was decreased; however, no rare variant was detected in the patient's APOC2 gene. Fifty single nucleotide variants were detected in the patient's APOC2, but all were common variants (allele frequencies ＞35%) that are supposedly not causative. Conclusions: A case of apoC-Ⅱ deficiency was found that is phenotypically identical to hypoapoC-Ⅱ but with no causative mutations in APOC2, implying that other genes regulate apoC-Ⅱ levels. The clinical entity of hypoapoC-Ⅱ is discussed. Thromb, 2013; 20:481-493. 
Introduction
Hypertriglyceridemia is of clinical importance not only as a sign of metabolic syndrome, but also as an independent risk factor for cardiovascular events [1] [2] [3] . Elucidation of the mechanisms of hypertriglyceridemia is an emerging need with the worldwide preva-lence of metabolic syndrome. Triglycerides (TG) are carried in the form of TG-rich lipoproteins (TGRL) in plasma. TGRLs are secreted either as chylomicrons from the intestine or as very low density lipoproteins (VLDL) from the liver, followed by catabolism by lipoprotein lipase (LPL) that hydrolyzes TGs in TGRL with subsequent uptake of remnant lipoproteins primarily by the liver. A defect in one of these pathways results in hypertriglyceridemia 4) .
ApoC-Ⅱ, a member of the apoE/apoC-Ⅰ/apoC-Ⅳ/apoC-Ⅱ gene cluster, is a 79-amino-acid polypeptide primarily biosynthesized in the liver and intestine, and is present on plasma chylomicrons, VLDL, and high-density lipoproteins (HDL). ApoC-Ⅱ plays an important role as a co-factor of LPL 5, 6) . The importance of apoC-Ⅱ in regulating plasma TG levels is evidenced by human apoC-Ⅱ deficiency 7) , which is a rare autosomal recessive disorder characterized by extreme hypertriglyceridemia, as seen in LPL deficiency 8, 9) .
The molecular defects of apoC-Ⅱ deficiency are heterogeneous. Most cases had causative mutations in the protein-coding region of the apoC-Ⅱ gene (APOC2) 10) , resulting in null apoC-Ⅱ (an initiation codon mutation 11) ), or nonfunctional apoC-Ⅱ protein (nonsense mutations 12) ; frameshift mutations 13) ; missense mutations 14) (reviewed in 15, 16) )). Notably, several cases were reported to have markedly reduced, but detectable levels of apoC-Ⅱ protein with apparently normal electrophoretic patterns (for simplicity, hereafter referred to as hypoapoC-Ⅱ) [17] [18] [19] . These are all characterized by a reduction in apoC-Ⅱ mRNA transcription due to i) decreased promoter activity of APOC2 (apoC-ⅡKöln 19) ), or ii) a donor splice-site mutation of intron 2 of APOC2 that results in markedly reduced levels of apoC-Ⅱ mRNA (ApoC-ⅡHamburg 17) , ApoC-ⅡTokyo 18) ).
We report a patient with apoC-Ⅱ deficiency in which no causative mutations were detected in the apoC-Ⅱ gene. Our patient is a typical case of hypo-apoC-Ⅱ manifesting hypertriglyceridemia, coincided with markedly reduced, but detectable levels of apoC-Ⅱ in plasma. As in other reported cases of hypoapoC-Ⅱ, apoC-Ⅱ mRNA transcription was decreased by 50%, at least partially due to reduced transcriptional activity of the cis-regulatory region of the patient's APOC2 gene, as shown by minigene reporter experiments. However, no rare variant was identified in any regions of APOC2, suggesting the involvement of additional genetic defect(s) that regulate apoC-Ⅱ protein levels in plasma. To our knowledge, this is the first report of apoC-Ⅱ deficiency with no rare variant found in the APOC2 gene. Together with other cases [17] [18] [19] , the clinical entity of hypoapoC-Ⅱ is discussed.
Methods

Subjects
The proband was a 47-year-old Japanese man manifesting type Ⅰ hyperlipidemia (plasma level of triglycerides, 3235 mg · dL −1 ; total cholesterol, 385 mg · dL −1 ) with recurrent episodes of pancreatitis. This patient was previously characterized and reported as having apoC-Ⅱ deficiency 20) . The diagnosis of apoC-Ⅱ deficiency was made based on undetectable levels of apoC-Ⅱ protein by the immunodiffusion assay. On referral to our hospital, he had been treated with fenofibrate and ethyl icosapentate. He also had a past medical history of conversion disorder with several episodes of cataplexy starting at age 36 years. Detailed clinical characteristics are available in Table 1 as well as in the previous report 20) .
In addition to the proband, his normolipidemic parent (mother) was investigated. Unrelated control subjects without hypertriglyceridemia were also investigated. His father's biological sample was unavailable since he had died at age 42 years with the diagnosis of cerebral vascular disease. Although his parents were not related, we found a case of consanguinity in his family (the patient's uncle and aunt were related), and consanguinity was rather common in the local community where both of his parents were raised.
Informed consent was obtained from the subjects, and all procedures were subjected to approval by the human genome, gene analysis research ethics committee of the University of Tokyo. activity in the absence of 1 mol·L −1 NaCl (total lipase activity). Various amounts of plasma from normolipidemic subjects were added to the assay mixture to supply an excess amount of apoC-Ⅱ proteins.
Northern Blot Analysis of Primary Monocytes/ Macrophages Derived from Peripheral Blood
Human monocytes/macrophages were isolated from peripheral blood by Lymphoprep (Nycomed, Roskiled, Denmark), and cultured as described previously 23) . On day 7, cells were incubated with or without 10 μmol ·L −1 of Liver X receptor (LXR) agonist (T0901317) for 24 h, and harvested. In a separate experiment, actinomycin D (Sigma-Aldrich, Tokyo, Japan) was added to the incubation medium at 10 μg ·L −1 to inhibit RNA synthesis.
Total RNA was isolated from cells by TRIzol reagent (Invitrogen Corp., Tokyo, Japan), and equal amounts of RNA were subjected to Northern blot analysis as described 23) . Probes for apoC-Ⅱ, apoC-Ⅳ, cleft lip and palate associated transmembrane protein 1 (CLPTM1), and monocyte colony stimulating factor (MCSF) were constructed from cDNA fragments amplified by RT-PCR using cDNA obtained from monocytes/macrophages as a template. Probes for apoE and ribosomal protein, large, P0 (RPLP0) were previously described 23, 24) . Primer sequences used for each probe construction are listed in Table 2 . Signals were detected and analyzed by Phosphor-Imager Screen and BASTATION software (FUJIFILM Corp., Tokyo, Japan). Intensity of each band was measured by ImageJ 1.39 software (NIH).
Southern Blot Analysis and Genomic DNA Copy Number Analysis
Genomic DNA (10 μg/reaction) were digested with 5 units of XbaI, SacI, PstI, EcoRI and BamHI (New England Biolabs, Beverly, MA, USA) at 37 ℃
Biochemical Analyses of Plasma Apolipoproteins
Blood was obtained from the patient, his mother, and normal control subjects. Fractions of plasma, buffy coat and total blood cells were separated by low-speed centrifugation. The buffy coat was stored at −80 ℃ until processed later to obtain genomic DNA as described in the following section. One microliter of plasma was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblot analysis using anti-human apoC-Ⅱ polyclonal antibody (Calbiochem, San Diego, CA, USA). Apolipoprotein control serum-Daiichi High (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan), was used as a standard to assess plasma concentrations of apoC-Ⅱ.
For isoelectric focusing (IEF) of plasma apolipoproteins, TGRLs, isolated by ultracentrifugation, were delipidated with ethanol:diethylether (3:1) to obtain apolipoproteins, which were then subjected to electrophoresis using Immobiline DryStrip (pH 4-7; GE Healthcare, Tokyo, Japan) according to the manufacturer's instructions; proteins were visualized by Coomassie brilliant blue staining. For two-dimensional PAGE (2D-PAGE), TGRL apolipoproteins were separated by IEF, then by SDS-PAGE, and apoC-Ⅱ protein was detected by immunoblotting using the same anti-apoC-Ⅱ antibody as described above.
Lipase Activity Assay
Post-heparin plasma (PHP) was obtained 15 min after an intravenous injection of heparin (30 units·kg −1 ) to overnight fasted subjects. Lipase activity in plasma (6.7 μL/reaction) was determined by measuring the amount of FFA released from 3 H-triolein emulsions (Amersham Biosciences, Tokyo, Japan) as described previously 21, 22) , and expressed as μmol −1 ·h −1 ·mL −1 . LPL activity was calculated by subtracting the activity in the presence of 1 mol·L −1 NaCl (representing hepatic triglyceride lipase (HTGL) activity) from the 
uct of the APOC2 gene as described above was cloned into pGEM-T Easy vector (Promega Corporation, Madison, WI, USA) using the In-Fusion PCR Cloning Kit (Clontech Laboratories, Inc., Mountain View, CA, USA); thereafter, the firefly luciferase gene was inserted just before the apoC-Ⅱ stop codon to generate an APOC2 minigene reporter construct. HEK293 cells and HepG2 cells were plated in a 48-well plate in triplicate, followed by transient transfection with 300 ng of the reporter construct along with 20 ng Renilla expression vector (pRL-SV40 (Promega), as a transfection control) using Attractene transfection reagent (Qiagen). Cells were lysed 48 h after transfection and cell lysates were used for the measurement of firefly and Renilla luciferase activities according to the supplier's instructions (Promega for firefly luciferase; Toyo B-Net Co., Ltd (Tokyo, Japan) for Renilla luciferase). The firefly luciferase activities were normalized against control Renilla luciferase activities.
Genotyping of Single Nucleotide Polymorphisms (SNPs) in APOC2
We included 384 persons who participated in an annual health check conducted by the Hiroshima Atomic Bomb Casualty Council Health Management Center (Hiroshima, Japan). Written informed consent was obtained from all the participants. We genotyped variants by direct sequencing, performed with the Big-Dye terminator (Life Technologies, Carlsbad, CA) and resolved by an ABI 3700 automated DNA sequencer (Life Technologies). The results were integrated using a Sequencher (Gene Codes, Ann Arbor, MI). Variants were genotyped manually. overnight, and subjected to Southern blot analysis as described previously 22) .
For DNA copy number analysis, genomic DNA (25 ng/reaction) was subjected to real-time PCR by LightCycler 480 system Ⅱ (Roche Applied Science, Tokyo, Japan) to amplify the APOC2 gene and RPLP0 gene (as a control). Primer pairs ( Table 3) were designed to amplify genomic DNA, but not mRNA. Cycle numbers for a given threshold were determined for both APOC2 and RPLP0, and the relative DNA copy number (APOC2/RPLP0) was calculated.
Sequencing the APOC2 and Other Genes in Plasma TG Metabolism
Genomic DNA was extracted from the buffy coat obtained from peripheral blood as described above, using the Blood & Cell Culture DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. The APOC2 gene, spanning from the 3' end of the last exon of the APOC4 to the 5' end of the first exon of CLPTM1, was amplified by PCR using genomic DNA (0.1 μg/reaction), PrimeSTAR GXL DNA polymerase (Takara Bio Inc., Otsu, Japan), and a set of primer pairs as listed in Table 4 . The PCR condition was as follows: 30 cycles of denaturation (98 ℃ for 10s) and extension (68 ℃ for 1 min/kb). The PCR fragment was purified by the MinElute Gel Extraction Kit (Qiagen), and sequenced using DNA sequencer CEQ 2000 (Beckman Coulter, Inc., Tokyo, Japan) with primers described in Table 5 . Alternatively, 3 to 7 subclones were sequenced to compensate for possible errors during extension with GXL polymerase. Other genes involved in plasma TG metabolism (LPL, apolipoprotein A-V (APOA5), apolipoprotein C-Ⅲ (APOC3), lipase maturation factor 1 (LMF1), GPI-anchored high-density lipoprotein (HDL)-binding protein 1 (GPIHBP1)) were sequenced as described 25, 26) .
Dual Luciferase Reporter Gene Assays
Reporter constructs containing the APOC2 minigene were constructed as follows: The PCR prod- Table 3 . Sequences of PCR primers for DNA copy number analysis
Target gene
Sequences of forward and reverse primers PCR product bp erozygotic cases of apoC-Ⅱ deficiency (1.8±0.5 mg · dL −1 ) 28) . Notably, the molecular weight of the patient's apoC-Ⅱ was identical to that of the normal subject. The electrophoretic patterns of the patient's residual apoC-Ⅱ were also indistinguishable from that of the normal subject as demonstrated by IEF ( Fig. 1B) or by 2D-PAGE ( Fig. 1C) , suggesting that the patient's plasma contains apoC-Ⅱ protein, albeit at markedly reduced levels. These phenotypes are compatible with those of the reported cases of hypoapoC-Ⅱ [17] [18] [19] .
Lipoprotein Lipase Activity in Post-Heparin Plasma (PHP)
Next, we assessed if LPL activity was impaired in the patient's plasma. Without the addition of normal plasma, LPL activity of the patient's PHP was reduced by 48% compared with that of the control subject (control vs. the patient: 8.6 vs. 4.5 μmol ·h −1 · mL −1 ). Addition of normal plasma dose-dependently increased the patient's LPL activity by 1.5-fold (4.5,
Statistical Analyses
Results are presented as the means±SE. Student's t -test was employed to compare the means between two groups. All calculations were performed with Stat View version 5.0 for Windows (SAS Institute Japan Ltd., Tokyo, Japan).
Results
Electrophoretic Analysis of Plasma ApoC-Ⅱ Protein
First, we performed immunoblot analysis of the patient's serum using anti-human apoC-Ⅱ polyclonal antibody to assess if the patient's serum was deficient in apoC-Ⅱ even with this highly sensitive method. Unexpectedly, a trace amount of apoC-Ⅱ protein was identified in the patient's plasma (Fig. 1A) . The concentration of apoC-Ⅱ in the patient's plasma was estimated to be 0.6 mg ·dL −1 , which was well below the average plasma apoC-Ⅱ concentration of healthy Japanese subjects (2.9±1.3 mg·dL −1 ) 27) , and that of het- subject but not that of the patient. To exclude the possibility that one of the APOC2 alleles was missing from the patient's genome, the DNA copy number of the APOC2 gene relative to the control gene, RPLP0, was examined by real-time PCR, revealing no major 5.8, and 6.6 μmol ·h −1 ·mL −1 , by the addition of 0, 0.5, and 1 μL of normal plasma, respectively), indicating that the patient's plasma lacked a co-factor for LPL, but not LPL per se. HTGL activity was found to be reduced in the patient's PHP (control vs. the patient: 10.3 vs. 2.4 μmol ·h −1 ·mL −1 ), as often seen in homozygous apoC-Ⅱ deficiency for unknown reasons 6) .
Northern Blot Analysis of Primary Monocytes/ Macrophages Derived from Peripheral Blood
One possible explanation for the decreased levels of plasma apoC-Ⅱ protein might be some defects in apoC-Ⅱ mRNA transcription, as reported in other cases of hypoapoC-Ⅱ. To rule out this possibility, we first measured mRNA levels of apoC-Ⅱ in monocytes/ macrophages isolated from peripheral blood, known cell types that express apoC-Ⅱ endogenously 29) . With only 2 μg of total RNA loaded, we successfully detected abundant mRNA expression of apoC-Ⅱ in the monocytes/macrophages of normal control subjects ( Fig. 2A) . In contrast, the patient's monocytes/macrophages showed 60% reduction in apoC-Ⅱ mRNA compared with normal control subjects, whereas the mRNA levels remained unchanged for all other genes tested: apoC-Ⅳ and apoE, genes in the same gene cluster; CLPTM1, a gene located 3' downstream of apoC-Ⅱ; MCSF and RPLP0, control genes ( Fig. 2A, left) . Importantly, the size of apoC-Ⅱ mRNA of the patient was identical to that of normal subjects. Incubation with LXR agonist (T0901317), which is known to upregulate the transcription of genes in the apoE/C-Ⅰ/ C-Ⅱ/C-Ⅳ gene cluster, increased apoC-Ⅱ mRNA levels in the cells of both the patient and controls to similar extents (controls, 1.7-and 1.4-fold; patient, 2-fold), indicating that the response to LXR agonist is well preserved in the patient's cells ( Fig. 2A, right) . ApoC-Ⅱ mRNA levels in the patient's cells were decreased by 53% compared with control cells even in the presence of LXR agonist. As demonstrated by actinomycin D experiment (Fig. 2B) , the stability of apoC-Ⅱ mRNA was not different between the patient and normal subject, suggesting that transcription of apoC-Ⅱ mRNA was impaired in the patient's cells.
Southern Blot and Genomic DNA Copy Number Analyses of the APOC2 Gene
To rule out the possibility that reduced levels of apoC-Ⅱ mRNA resulted from a major gene rearrangement, we performed Southern blot analysis (Fig. 3A) .
No difference was observed between the patient and control samples for all enzymes tested except for SacI, which is due to SNP rs5120 in intron 1 ( Table 6) , resulting in SacI digestion in the DNA of the control (A) Immunoblot analysis of apoC-Ⅱ. One μL of plasma from the patient (Pt), control subject (C), or apolipoprotein control serum (Daiichi High; Daiichi Pure Chemicals Co., Ltd.) with various concentrations of apoC-Ⅱ, was subjected to SDS-PAGE followed by immunoblotting using anti-human apoC-Ⅱ polyclonal antibody. (B) For isoelectric focusing of apolipoproteins, 30 μg of delipidated TGRL apolipoproteins was subjected to electrophoresis using Immobiline DryStrip (pH4-7), followed by Coomassie Brilliant Blue staining. (C) For two-dimensional PAGE of apolipoproteins, 2 μg of delipidated TGRL apolipoproteins was electrophoresed as described in Methods. ApoC-Ⅱ protein was detected by immunoblotting as described above.
A B C
APOC2 Minigene Reporter Assay
To determine if decreased apoC-Ⅱ mRNA transcription in the patient's cells is due to decreased transcriptional activity of the cis -regulatory regions of the difference between the patient and two control subjects ( Fig. 3B) . A B patient's APOC2 gene, we constructed reporter constructs of the APOC2 minigene amplified from genomic DNA of the patient and control subject; subsequently, the luciferase gene was cloned just before the stop codon of the APOC2 gene (Fig. 4A) . Transient transfection of these constructs to HEK293 cells or HepG2 cells revealed that transcriptional activity of the patient's minigene was significantly decreased by 39% and 51%, respectively, compared with that of the control construct (Fig. 4B) . These results demonstrate that transcriptional repression of the patient's APOC2 gene is at least partially due to a functional defect in the cis-regulatory region of the APOC2 gene.
Sequencing of the APOC2 and Other Genes in Plasma TG Metabolism
Next, we sought to identify if there are any sequence variants in the APOC2 gene of the patient that account(s) for the extremely low levels of apoC-Ⅱ proteins in the patient's plasma. Sequencing of APOC2 of the patient and control subject, followed by comparison with the reference sequence (NC_000019.9), revealed 50 SNPs ( Table 6 ). We also sequenced APOC2 of the patient's mother and found 42 SNPs that were heterozygous for the patient's mother and homozygous for the patient (data not shown); however, all of these SNPs were common variants with allele frequencies higher than 0.35 (as reported in the dbSNP database, or as identified by direct sequencing of Japanese individuals (n = 384) for the SNPs where allele frequencies were not reported in the dbSNP database). As apoC-Ⅱ deficiency is less frequent than LPL deficiency, which occurs in one in a million 30) , these common variants are unlikely to be the causative mutations.
Sequencing of other genes involved in plasma TG metabolism (LPL, APOA5, APOC3, LMF1 and GPIHBP1) revealed no rare variant in the patient's gene (data not shown). These results indicate that other yet-to-be-identified genes, which regulate plasma apoC-Ⅱ protein levels, are responsible for type Ⅰ hyperlipidemia associated with apoC-Ⅱ deficiency in this patient.
Discussion
ApoC-Ⅱ deficiency has been well characterized since its first description in 1978 7) . In most cases, homozygous mutations were identified in the proteincoding region, resulting in null, truncated, or nonfunctional apoC-Ⅱ protein 15, 16) ; however, several atypical cases of apoC-Ⅱ deficiency have been described, where apoC-Ⅱ is severely reduced in plasma, but still 
genes that regulate plasma apoC-Ⅱ concentration. The search for a defect (in genes, miRNAs, etc.) by whole-exome or whole-genome sequencing is of particular interest, which could reveal the yet-to-be-identified regulatory mechanisms of the apoC-Ⅱ protein.
While our data clearly showed that the transcriptional activity of the patient's APOC2 minigene was reduced by 50% compared with the normal subject ( Fig. 4B) with an accompanying 50% reduction in apoC-Ⅱ mRNA levels ( Fig. 2A) , apoC-Ⅱ protein levels are more profoundly reduced in the patient's plasma (0.6 mg·dL −1 ; Fig. 1A) : Compared with the apoC-Ⅱ protein levels in normolipidemic Japanese population (2.9 mg ·dL −1 ) 27) , the patient has only 21% of the normal amount of plasma apoC-Ⅱ protein. This discrepancy between apoC-Ⅱ protein and apoC-Ⅱ mRNA levels in the patient implies the yetto-be-identified causative genes that regulate apoC-Ⅱ protein levels at translational or post-translational levels. Alternatively, the causative genes could be some transcriptional factors that affect apoC-Ⅱ mRNA transcription, as the discrepancy may result from 1) the difference between the in vivo and in vitro milieu of transcriptional machinery, or 2) from the decreased transcription of apoC-Ⅱ mRNA in the liver or intestine in vivo.
Another important question is if this level of reduction in plasma apoC-Ⅱ (0.6 mg·dL −1 ) could explain the observed massive hypertriglyceridemia in this patient. In the seminal paper by Breckenridge et al., it was implied that only 5-10% of the normal levels of apoC-Ⅱ would be sufficient to keep plasma triglycerides levels within the normal range 7) . Considering that plasma apoC-Ⅱ concentration of the patient is only 21% of that of normolipidemic Japanese popu-detectable (named hypoapoC-Ⅱ). In these cases, homozygous mutations were found in the promoter region 19) or in the donor splice site 17, 18) of APOC2, resulting in decreased transcription or defective processing of apoC-Ⅱ mRNA, respectively. Here we describe a new case of hypoapoC-Ⅱ with no causative mutations found in the APOC2 gene. Involvement of other genetic defects affecting plasma apoC-Ⅱ levels is clearly implied.
Our case was not due to mutations in the protein-coding region of APOC2 (Fig. 3, Table 6 ). Markedly reduced levels of plasma apoC-Ⅱ protein (Fig. 1) could result from decreased apoC-Ⅱ mRNA transcription, as reported in other cases of hypoapoC-Ⅱ [17] [18] [19] . In fact, we found about 50% reduction in endogenous apoC-Ⅱ mRNA levels in monocytes/macrophages of the patient ( Fig. 2A) with no apparent change in the rate of mRNA degradation (Fig. 2B) . We further detected about a 50% decrease in the transcriptional activity of the cis-regulatory region of the patient's APOC2 gene (Fig. 4B) ; however, all the SNPs contained in the cis-regulatory regions are common variants. By scrutinizing every type of apoC-Ⅱ deficiency reported so far, we conclude that this is a new case of apoC-Ⅱ deficiency without any rare variants in the APOC2 gene.
The major question here is what other genes cause extremely low levels of apoC-Ⅱ proteins in the patient's plasma, and exactly what molecular mechanism is involved. Currently, we do not have the answer to these questions. We sequenced other genes involved in plasma TG metabolism (LPL, APOA5, APOC3, LMF1 and GPIHBP1) and found no mutations or rare variants. The causative genetic defects in our patient would most likely involve other unknown (Cont Table 6 The frequency of C allele (the patient type) was 15.2% in 112 individuals, for whom PCR was successful in the control cohort (n = 384). and 6.14 mmol · L −1 (543 mg ·dL −1 ), in the fasted and fed states, respectively) 31) . This phenotypic heterogeneity may result from additional nutritional, environmental, or other genetic factors such as apoE genotype, as mentioned previously 18, 32) . In other words, hypoapoC-Ⅱ might be a common genetic predisposition to hypertriglyceridemia requiring additional lation as calculated above 27) , this level of hypoapoC-Ⅱ would not be sufficient to explain hypertriglyceridemia in this patient per se. Indeed, another case of hypoapoC-Ⅱ with similar plasma apoC-Ⅱ concentration (0.5 mg·dL −1 ) was reported by Kawano et al., where the patient only had moderate postprandial hypertriglyceridemia (1.46 mmol·L −1 (129 mg ·dL −1 ) Fig. 4 . Minigene reporter assay.
(A) The APOC2 minigene, spanning from the 3' end of the last exon of APOC4 to the 5' end of the first exon of CLPTM1, were cloned to pGEM-T easy vector, followed by insertion of the firefly luciferase gene just before the stop codon of APOC2. (B) HEK293 and HepG2 cells were transiently transfected with these minigene reporter constructs along with Renilla luciferase plasmid as a transfection control. Relative luciferase activity (RLU) was calculated by dividing firefly luciferase activity by Renilla luciferase activity. Data are expressed as the average± SE of triplicate wells ( ＊ p＜0.01; ＊ ＊ p＜0.005).
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genetic/environmental/nutritional factors to develop severe hypertriglyceridemia. Further research on additional genetic defects in hypoapoC-Ⅱ patients may address this issue.
A key feature of hypoapoC-Ⅱ reported so far is the decreased rate of transcription of apoC-Ⅱ mRNA [17] [18] [19] , which should accompany a decrease in apoC-Ⅱ mRNA levels in endogenous tissues; however, only one study directly demonstrated the reduction in apoC-Ⅱ mRNA, where they utilized a liver biopsy specimen 17) . Since the measurement of endogenous levels of apoC-Ⅱ is essential for the diagnosis of hypoapoC-Ⅱ, our method to detect endogenous levels of apoC-Ⅱ mRNA using monocytes/macrophages derived from peripheral blood provides a useful diagnostic tool for this subtype of apoC-Ⅱ deficiency. The culture system is also useful to explore the mechanism of decreased apoC-Ⅱ mRNA levels (Fig. 2) .
Conclusion
We report a new case of apoC-Ⅱ deficiency that is phenotypically identical to hypoapoC-Ⅱ, but with no causative mutations detected in the APOC2 gene. Our results clearly suggest the involvement of other genes that regulate plasma apoC-Ⅱ protein levels. Further studies on hypoapoC-Ⅱ may uncover the yet-tobe-identified molecular mechanisms that regulate apoC-Ⅱ and plasma TG metabolism.
